- Research article
- Open Access
- Open Peer Review
Improving the physician-patient cardiovascular risk dialogue to improve statin adherence
- Linda Casebeer†1Email author,
- Craig Huber†2,
- Nancy Bennett†3,
- Rachael Shillman†1,
- Maziar Abdolrasulnia†1,
- Gregory D Salinas†1 and
- Sijian Zhang†4
© Casebeer et al; licensee BioMed Central Ltd. 2009
- Received: 07 January 2009
- Accepted: 30 June 2009
- Published: 30 June 2009
The purpose of this study was to evaluate the effectiveness of a patient education program developed to facilitate statin adherence.
A controlled trial was designed to test the effectiveness of a multifaceted patient education program to facilitate statin adherence. The program included a brief, in-office physician counseling kit followed by patient mailings. The primary end point was adherence to filling statin prescriptions during a 120-day period. Patients new to statins enrolled and completed a survey. Data from a national pharmacy claims database were used to track adherence.
Patients new to statin therapy exposed to a patient counseling and education program achieved a 12.4 higher average number of statin prescription fill days and were 10% more likely to fill prescriptions for at least 120 days (p = .01).
Brief in-office counseling on cardiovascular risk followed by patient education mailings can be effective in increasing adherence. Physicians found a one-minute counseling tool and pocket guidelines useful in counseling patients.
- Statin Therapy
- Claim Database
- Statin Prescription
- Statin Medication
- Patient Education Program
Effective management of lipid levels as risk factors for cardiovascular disease requires long-term adherence to a lipid lowering treatment regimen. However, studies continue to demonstrate lack of persistence in adhering to cholesterol-lowering medicine therapy [1–6]. When individuals at risk for cardiovascular disease do not adhere to prescribed medical regimens, medication benefits are not fully achieved. Only half of individuals continue to take prescribed statins at six months, with further declines in adherence at one year . This finding is consistent in individuals who would benefit from primary prevention with statins, as well as in those who have experienced a cardiovascular event; it is especially prominent in asymptomatic individuals, where such treatment is preventive [6–8].
Understanding and improving the quality of medication management through the patient dialogue is a key issue in adherence by patients treated for chronic diseases [1, 9]. The communication of cardiovascular risk has been linked to patients intensifying risk-reducing behaviors and adhering to prescribed therapies . Medication side effects and cost issues that may lead to non-adherence are frequently not discussed with physicians, a communication gap with important quality and safety implications [11, 12]. Providers may also not be using the most effective communication strategies when they do ask about medication-taking behavior .
A review of randomized controlled trials evaluating the effectiveness of interventions designed to facilitate patient adherence to prescribed medications for chronic health problems found that effective interventions were complex, labor-intensive, and not predictably effective . A recent analysis addressing how adherence to statins could be improved found that simplification of drug regimens, patient information and education and intensified patient care by healthcare professionals showed the most promise . At the present time, no fully effective strategies for adherence are in widespread clinical use; innovative approaches to assist patients in following prescriptions have the potential to enhance the health of the public and reduce healthcare costs . Risk-communication interventions, however, have been associated with improved patient knowledge, perception of risk, and adherence. [14, 15] The extra consultation time required for risk counseling and shared decision-making has been associated with benefits to the patient. 
When patients begin a new medical regimen, the regimen requires behavioral changes both in implementation and maintenance. The transtheoretical model has been used to describe patients' willingness to make behavioral changes that benefit their health. The model postulates that patients, as they make changes such as adhering to a newly prescribed medical regimen, evolve throughout six stages: precontemplation, contemplation, preparation, action, maintenance, and termination.  A review of the use of the transtheoretical model in medication adherence revealed that the model has not been used extensively to investigate medication use, although the model has shown promise as a context for developing interventions to improve adherence. 
The purpose of this study was to evaluate the effectiveness of an innovative patient educational program focused on risk counseling, designed to facilitate patient adherence to statin prescriptions. A secondary purpose was to determine whether the program would be more effective with patients who take action proactively to preserve their health.
A controlled trial was designed to test the effectiveness of the Heart Health Counts (HHC) program. This patient education program was designed to increase clarity in the cardiovascular risk dialogue, in order to facilitate statin adherence. The primary end point was adherence to filling statin prescriptions during a 120-day period by patients new to statin therapy.
To enroll, patients were asked to complete a consent form, and to complete a survey. Patients were enrolled at the time of a visit to their physician and were eligible to participate if they were at least 40-years of age and receiving a new prescription for statin therapy. Survey items of attitudes and beliefs related to cardiovascular disease and cholesterol management were included.
Identifying patients according to their attitudes concerning health and lifestyle change has been shown to be important in developing strategies to facilitate behavioral change .
Based on their survey responses, patients were categorized into three segments according to their health and medication attitudes: patients who regularly take action to preserve their health, patients committed to their health but not consistently taking action, and patients who do less to preserve health.
Data on statin prescription use from a national pharmacy claims database were used to determine whether or not patients achieved 120 day adherence. Based on region, prescription, age and gender, a control group of similar patients not exposed to the patient education intervention were identified from the national pharmacy claims database. The Western Institutional Review Board approved the study in October of 2006. Patients and physicians completed a consent form agreeing to participate. Physicians also completed a brief survey on their perceptions of the program following use of the brief counseling materials with their patients.
Physicians were eligible to participate if they provided adult primary care or were cardiologists. Physicians were required to read the protocol, to complete a brief online module concerning counseling patients with high cholesterol, and to complete a consent form and letter of agreement. Patients were eligible to participate if they are 40 years of age or older, had received a prescription for a lipid-lowering agent within the past 30 days, had not previously been on a cholesterol-lowering medicine within the past 12 months, were literate in English, and able to give written consent to receive patient educational mailings.
Power calculations indicated, within 95% confidence intervals, a sample including at least 200 patients (including 50 in each of two specific segments, those characterized as Health Preservers and those characterized as Health Commiteds), a total of 100 patients was needed to detect a 5% difference in adherence to statins at 120 days comparing segments to a control group. In order to determine the number of patients required for enrollment, it was estimated that each of the two segments of patients who were ready to act to preserve their health were representative of less than 10% of the total population, and a smaller percentage of these would actually fill their prescriptions. It was further estimated that 200 physicians were needed to each recruit approximately 10 patients with hypercholesterolemia new to statin therapy, a total of 2000 patients. Physicians were each allowed to recruit no more than 15 patients in order to ensure balanced representation among the physicians recruited. Reflecting the 95% confidence intervals, the significance level was set at .05.
Five questions from the 20-question survey were used to segment patients into three groups. These questions were used to create segments, but were not validated for this purpose. Patients were asked to respond to the following statements using a 7-point agreement scale: 1) I feel tired most of the time 2) I feel older than I should 3) I do not care what is in the medication, just that it works 4) I am worried about the long-term side effects of medications and 5) Taking medication makes me feel like I'm doing everything I can to make myself better. Health Preservers were more likely to agree with question #5 and less likely to agree with questions 1,2,3, and 4. Health Committeds were more likely to agree with question 3 but less likely to agree with questions 1, 2 and 5. Others, those patients who were less likely to focus on health preservation, were more likely to agree with questions 1, 2, and 4, and less likely to agree with questions 3 or 5.
Data from a national pharmacy claims database were used to determine adherence to filling statin prescriptions. The average number of days for which statin prescriptions were written was 30 days. However, the number of days for which statin prescriptions were filled varied between sites and depended on the site's current supplies. Therefore, days of filled statin prescriptions were used in this study, rather than the number of prescriptions filled. Two adherence measures were calculated: 1) the average number of days of prescriptions filled for statins per patient during a 120-day time period, and 2) the percentage of patients who filled prescriptions for 120 days of statin therapy.
The HHC program provided tools to physicians to increase clarity in the cardiovascular risk dialogue, in order to facilitate statin adherence. The program was designed to facilitate an enhanced patient-physician dialogue without being labor-intensive for physicians and other healthcare providers. Physicians participating in this study received a counseling kit including 1) a set of 1-minute health manager patient education tools used to describe cholesterol risks, 2) patient contracts or pledges designed to confirm a patient's commitment to the prescribed medical regimen, 3) a copy of the National Cholesterol Education Program pocket guidelines and 4) a set of chart stickers. The materials were designed to address cardiovascular risk and to provide a context for patients who might be presented with a series of lab values but might not have a context for the severity of the risk. The 1-minute health manager and other HHC materials used color coding with green, yellow, and red to represent cardiovascular risk stratification, and to serve as a call to action for patients in the yellow and red zones. By fostering a more constructive patient-provider dialogue, a context could be created for a patient-physician partnership in developing achievable patient goals to reduce the risk of cardiovascular disease.
Following the office visit, patients new to statin therapy received 5 HHC mailings over a 4-month period. The four-color print mailings focused on various aspects of cardiovascular health and cardiovascular risk.
Descriptive statistics for categorical data were expressed as percentages; for the continuous data, the descriptive statistics were expressed as means (standard deviations). T-tests were used to compare the average numbers of days statin prescriptions were filled, and the percentage of patients who completed 120 days of statin therapy. On questions 1 and 4, a reflect and square root transformation was performed to normalize a distribution that differs only moderately from normal. The deviation is more substantial for questions 3 and 5, so we performed a reflect and inverse transformation. Comparisons of segmented groups were quantified by one-way multivariate analysis of variance (MANOVA), followed by post-hoc pairwise comparisons using the Student-Newman-Keuls (SNK) test and the Dunnett T3 test for data sets with unequal variances. Statistical significance was established as p < 0.05. All analyses were conducted using SPSS 16.0 (SPSS, Inc. Chicago, IL).
Physician patient communication by segment
1. Has your physician talked to you about drug treatments to lower your cholesterol?
2. Has your physician talked to you about your current cholesterol levels?
3. Did your physician talk to you about health risks of high cholesterol?
4. Has your physician talked to you about your cholesterol goals?
5. Do you feel your doctor has listened carefully to you?
6. Do you feel your doctor has explained things in a way you could understand?
7. Do you usually raise your concerns even when your doctor does not ask?
Patients matched to pharmacy claims database by segment
Patients By Segment
Matched to Claims Data1
New Statin Script Filled2
Matched Patients Filling Statin Script
Total Heart Health Counts Patients
Days of new statin prescriptions filled
Enrolled Patient Segments
Mean # Days*
% Completing 120 days*
Segments Compared to Control
All Heart Health Counts Patients
All Control Patients
Patient attitudes concerning cardiovascular risk related to elevated cholesterol
η p 2
How concerned are you about your cholesterol level?
My cholesterol level does not make a big difference to my total overall health.
People with high cholesterol are more likely to have a heart attack than people with low cholesterol.
I am confident I can do what is needed to manage my cholesterol.
P < R
C < R
P ≠ other
C ≠ other
Taking medicine every day to lower cholesterol is worth it to me to lower the chances of having a heart attack in the future.
Ratings of usefulness of Heart Health Counts kit components N = 164
One-Minute Health Manager Profile
Hearth Health Counts Pledge
NCEP ATP III Pocket Guidelines
While the use of statin medication has clinically proven benefits in the treatment of heart disease, one of the well-documented barriers to its use is the large number of patients who do not fill the prescription, or stop use within the first year. Improving adherence to a treatment plan may result from a better understanding by the individual of personal risk as well as of the disease process and the role of statin medication in reducing cardiovascular risk. The HHC program has focused on the communication of cardiovascular risk in the dialogue between patient and physician in order to motivate the patient to adhere to the prescribed medical regimen.
Patients participating in the HHC study filled more prescriptions than control patients who were not exposed to the program. Based on the research highlighting the difficulties associated with labor-intensive interventions [2, 5], the program was designed to intensify the physician patient dialogue without becoming labor intensive. The Heart Health Counts program aimed at maximizing the limited amount of time a physician might spend with a patient during the patient encounter by providing a simple, well-designed 1-minute risk counseling tool. Physicians stressed the benefits of the 1-minute cardiovascular risk manage tool and a pocket cholesterol management guideline, reporting that these tools facilitated patient management.
Given the scarce resources available for increasing adherence, the concept of segmentation for health education based on health beliefs has the potential to identify those patients who will benefit most from additional counseling and reinforcement of the benefits from a given treatment plan. The Heart Health Counts program was most effective with those individuals classified as Health Preservers, a group whose beliefs included a commitment to actively preserving their health. Physician-patient communication may be enhanced when a physician better understands a patient's approach to his/her own care [18–20] More research is needed, however, to better understand how to best design tailored interventions.
This study was limited in several ways. The use of prescribing data from retail pharmacies as a data source presents a series of limitations. The claims database captured commercial pharmacy data, but did not capture all events related to patient pharmacy claims Patients may have filled prescriptions in some other setting, by mail, or not at all. Using a national claims database does not allow a complete study of nonadherence since not all patients are represented in the database. Patient prescribing data is deidentified and aggregated by segment; thus, prescription data could not be connected to survey data. Filling a prescription did not actually guarantee taking the medicine. In future studies, more robust measures of adherence could track actual medication use by recording the dates and times of medicine bottle opening with electronic caps.
The study was also limited by the study period, where adherence was measured at 120 days. A longer period of follow-up would provide a more in-depth look at adherence patterns. The current study was not designed to track actual exposure to the mailed materials, leaving open the research question concerning the effectiveness of whether tailored mailed patient education materials increase statin adherence. Future research to attempt to resolve this question could include the use of emerging technologies, such as Internet sites that would allow tracking exposure to educational messages.
In conclusion, providing tools to physicians to improve the quality of the physician-patient dialogue around cardiovascular risk shows promise in addressing the important issue of facilitating long-term adherence to statin therapy. Tools that increase the clarity of risk communication but do not add significantly to the labor of healthcare professionals are those that are most valuable in daily clinical practice.
Little attention has been paid in medical school and residency training programs in teaching physicians the best ways to communicate cardiovascular risk and to motivate patients to adhere to the prescribed medical regimens that prevent cardiovascular disease. Providing physicians and other healthcare professionals with tools to make the dialogue during the patient encounter more effective and efficient may significantly enhance patient adherence. Strategies that provide follow up for patients through reminders may reinforce the messages from this dialogue.
Patients vary in their attitudes towards their health and in taking on a new medical regimen. One size does not fit all in patient education and counseling. Simple strategies that support the physician-patient dialogue and those that provide reminders to patients about the need to reduce cardiovascular risk may have a significant impact on improving patient adherence and preventing cardiovascular disease.
The authors gratefully acknowledge the support of AstraZeneca in providing funding for this study, as well as IMS Health and Epsilon for their contributions in organizing data to examine statin adherence.
- Chaudhry HJ, McDermott B: Recognizing and improving patient nonadherence to statin therapy. Curr Atheroscler Rep. 2008, 10: 19-24. 10.1007/s11883-008-0004-4.View ArticlePubMedGoogle Scholar
- Schedlbauer A, Schroeder K, Fahey T: How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials. Fam Pract. 2007, 24: 380-387. 10.1093/fampra/cmm030.View ArticlePubMedGoogle Scholar
- Caspard H, Chan AK, Walker AM: The long-term course of low-density lipoprotein cholesterol after initiation of statin treatment: retrospective database analysis over 3 years in health maintenance organization enrollees. Clin Ther. 2005, 27: 1622-1628. 10.1016/j.clinthera.2005.09.004.View ArticlePubMedGoogle Scholar
- Huser MA, Evans TS, Berger V: Medication adherence trends with statins. Adv Ther. 2005, 22: 163-171. 10.1007/BF02849887.View ArticlePubMedGoogle Scholar
- McDonald HP, Garg AX, Haynes RB: Interventions to Enhance Patient Adherence to Medication Prescriptions. Scientific Review. JAMA. 2002, 288: 2868-2879. 10.1001/jama.288.22.2868.View ArticlePubMedGoogle Scholar
- Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002, 288: 462-467. 10.1001/jama.288.4.462.View ArticlePubMedGoogle Scholar
- Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM: Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004, 19: 638-645. 10.1111/j.1525-1497.2004.30516.x.View ArticlePubMedPubMed CentralGoogle Scholar
- La Rosa JH, La Rosa JC: Enhancing Drug Compliance in Lipid-Lowering Treatment. Arch Fam Med. 2000, 9: 1169-1175. 10.1001/archfami.9.10.1169.View ArticleGoogle Scholar
- Bokhour BG, Berlowitz DR, Long JA, Kressin NR: How do providers assess antihypertensive medication adherence in medical encounters?. J Gen Intern Med. 2006, 21: 577-583. 10.1111/j.1525-1497.2006.00397.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Roach P, Marrero D: A critical dialogue: communicating with type 2 diabetes patients about cardiovascular risk. Vasc Health Risk Manag. 2005, 1: 301-307. 10.2147/vhrm.2005.1.4.301.View ArticlePubMedPubMed CentralGoogle Scholar
- Wilson IB, Schoen C, Neuman P, Stollo MK, Rogers WH, Chang H, Safran DG: Physician-patient communication about prescription medication nonadherence: a 50 state study of America's seniors. J Gen Intern Med. 2007, 22: 6-12. 10.1007/s11606-006-0093-0.View ArticlePubMedPubMed CentralGoogle Scholar
- Tija J, Givens JL, Karlawish JH, Okoli-Umeweni A, Barg FK: Beneath the surface: discovering the unvoiced concerns of older adults with type 2 diabetes mellitus. Health Educ Res. 2008, 23: 40-52. 10.1093/her/cyl161.View ArticleGoogle Scholar
- Lee JK, Grace KA, Taylor AJ: Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006, 296: 2563-2571. 10.1001/jama.296.21.joc60162.View ArticlePubMedGoogle Scholar
- Edwards A, Elwyn G: How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature. Med Decis Making. 1999, 19: 428-434. 10.1177/0272989X9901900411.View ArticlePubMedGoogle Scholar
- Edwards A, Elwyn G, Hood K, Atwell C, Robling M, Houston H, Kinnersley P, Rusell T, Study Steering Group: Patient-based outcome results from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice. Fam Pract. 2004, 21: 347-354. 10.1093/fampra/cmh402.View ArticlePubMedGoogle Scholar
- Prochaska JO, Velicer WF: The transtheoretical model of health behavior change. Am J Health Promo. 1997, 12: 38-48.View ArticleGoogle Scholar
- Ficke DL, Farris KB: Use of the transtheoretical model in the medication use process. Ann Pharmacother. 2005, 39: 1325-1330. 10.1345/aph.1G122.View ArticlePubMedGoogle Scholar
- Cheraghi-Sohi S, Hole AR, Mead N, McDonald R, Whalley D, Bower P, Roland M: What patients want from primary care consultations: a discrete choice experiment to identify patients' priorities. Ann Fam Med. 2008, 6: 107-115. 10.1370/afm.816.View ArticlePubMedPubMed CentralGoogle Scholar
- Haggerty J, Tudiver F, Brown JB, Herbert C, Ciampi A, Guilbert R: Patients' anxiety and expectations: how they influence family physicians' decisions to order cancer screening tests. Can Fam Physician. 2005, 51: 1658-1659.PubMedGoogle Scholar
- Elwyn G, Edwards A, Kinnersley P: Shared decision-making in primary care: the neglected second half of the consultation. Br J Gen Pract. 1999, 49: 477-482.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2296/10/48/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.